

Significant heterogeneity in [dual antiplatelet therapy](#) regimens following [Pipeline Embolization Device \(PED\)](#) placement and associated costs, exists at major academic [neurovascular centers](#). The most commonly used first line dual antiplatelet regimen consists of [aspirin](#) and [clopidogrel](#). Two major alternate protocols involving [ticagrelor](#) and [prasugrel](#), are administered to clopidogrel hypo-responders. The optimal dual antiplatelet regimen for patients with cerebrovascular conditions has not been established, given limited prospective data within the neurointerventional literature ¹⁾.

¹⁾

Gupta R, Moore JM, Griessenauer CJ, Adeeb N, Patel AS, Youn R, Poliskey K, Thomas AJ, Ogilvy CS. Assessment of Dual Antiplatelet Regimen for Pipeline Embolization Device Placement: A Survey of Major Academic Neurovascular Centers in the United States. World Neurosurg. 2016 Sep 15. pii: S1878-8750(16)30839-7. doi: 10.1016/j.wneu.2016.09.013. [Epub ahead of print] PubMed PMID: 27641263.

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

<https://neurosurgerywiki.com/wiki/doku.php?id=ticagrelor>

Last update: **2025/04/29 20:22**

